Synageva BioPharma™ Announces Presentations and a Satellite Symposium at the National Lipid Association Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)-- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association (NLA) annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013. The titles to the three posters on display during the conference are:
Identifying Cases of Cholesteryl Ester Storage Disease in a Tertiary Lipid Clinic, JP Kane, et al
Dyslipidemia Profile in Cholesteryl Ester Storage Disease, R Tripuraneni, et al
Sebelipase Alfa Improves Dyslipidemia in Patients with Cholesteryl Ester Storage Disease, R Tripuraneni, et al
Synageva-sponsored satellite symposium
During the NLA meeting, Synageva sponsored a satellite symposium entitled, "Why the Lipidologist Should Care About Lysosomal Acid Lipase (LAL) Deficiency" chaired by Daniel J. Rader, M.D., Cooper-McLure Professor of Medicine and Pharmacology, Chief, Division of Translational Medicine and Human Genetics Associate Director, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania. The symposium was held May 31 at 7:30-9:00 a.m., PDT.
About Synagevas lead programs sebelipase alfa for LAL Deficiency and SBC-103 for MPS IIIB
LAL Deficiency is a rare autosomal recessive lysosomal storage disorder (LSD) caused by a marked decrease in LAL enzyme activity. Late onset LAL Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD), is an underappreciated cause of cirrhosis and accelerated atherosclerosis in children and adults. These complications are due to the buildup of fatty material in the liver and blood vessel walls as a result of decreased LAL enzyme activity. Early onset LAL Deficiency, sometimes called Wolman disease, is the most rapidly progressive form of LAL Deficiency and is usually fatal within the first six months of life. Affected infants develop severe malabsorption, growth failure and liver failure. There are no approved therapies for LAL Deficiency.
Sebelipase alfa (SBC-102) is a recombinant form of the human LAL enzyme under development by Synageva as an enzyme replacement therapy for LAL Deficiency. Synageva is evaluating sebelipase alfa in global clinical trials for both early and late onset LAL Deficiency. Sebelipase alfa has been granted orphan designations by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa received fast track designation by the FDA, and Breakthrough Therapy designation by the FDA for early onset LAL Deficiency.
The mucopolysaccharidoses (MPS) consist of a group of rare LSDs caused by a deficiency of enzymes needed to break down complex sugars called glycosaminoglycans. The MPS III syndromes (also known as Sanfilippo syndromes) share complications with other MPS diseases but represent a clinically distinct subset with marked central nervous system degeneration. Mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) is caused by a marked decrease in alpha-N-acetyl-glucosaminidase (NAGLU) enzyme activity which leads to the buildup of abnormal sugars called heparan sulfate disaccharides (HSD) in the brain and other organs. The accumulation of abnormal HSD, particularly in the central nervous system, leads to severe cognitive decline, behavioral problems, speech loss, increasing loss of mobility, and premature death. There are no approved therapies for MPS IIIB.
SBC-103 is a recombinant form of the human NAGLU enzyme under development by Synageva as an enzyme replacement therapy for MPS IIIB. Using various dosing approaches, SBC-103 reduced HSD substrate storage in the brains, liver and kidney tissues in an MPS IIIB animal model. SBC-103 has been granted orphan designation by the FDA and the EMA. Synageva plans to enter SBC-103 into human clinical trials for MPS IIIB during the first half of 2014.
About Synageva BioPharma Corp. (GEVA)
Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Synageva has several protein therapeutics in its drug development pipeline.
Synageva routinely posts information that may be important to investors in the Investor Relations section of our web site at www.synageva.com. Synageva encourages investors and potential investors to consult our web site regularly for important information about us.
Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.
This news release contains forward-looking statements. Such statements generally can be identified by the use of words such as anticipate, expect, plan, could, intend, believe, may, will, estimate, forecast, project, or words of similar meaning. These forward-looking statements address, among other matters, our plans to enter into human clinical trials for MPS IIIB. Many factors may cause actual results to differ materially from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, including an accurate understanding of the implications of Breakthrough Therapy designation which cannot be determined at this time, and the risks associated with transitioning our preclinical MPS IIIB program to human clinical trials and those additional risks identified under the heading Risk Factors in the Companys Annual Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2013, and other filings Synageva periodically makes with the SEC (SCUR), and others of which are not known. No forward-looking statement is a guarantee of future results or events, and investors should avoid placing undue reliance on such statements. Synageva undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Dedicated to Rare Diseases® is a registered trademark. Synageva BioPharma" is a trademark of Synageva BioPharma Corp.
Matthew Osborne, 781-357-9947
Source: Synageva BioPharma Corp.Copyright Business Wire 2013